This combination is used in the treatment of Type 2 Diabetes Mellitus to improve glycemic control when diet, exercise, or monotherapy is inadequate. Vildagliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion and suppresses glucagon release, while dapagliflozin, an SGLT2 inhibitor, lowers blood glucose by increasing urinary glucose excretion. Together, they effectively control both fasting and post-prandial blood glucose levels with a low risk of hypoglycemia and added benefits such as weight reduction and cardiovascular support.
